A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Public ClinicalTrials.gov record NCT06008093. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for First-line Treatment in Metastatic Non-small Cell Lung Cancer Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.
Study identification
- NCT ID
- NCT06008093
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 103 participants
Conditions and interventions
Conditions
Interventions
- Durvalumab Drug
- Tremelimumab Drug
- Pemetrexed Drug
- Pembrolizumab Drug
- Carboplatin Drug
- Cisplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 4, 2024 (Actual)
- Primary completion
- Oct 23, 2026 (Estimated)
- Completion
- Feb 28, 2028 (Estimated)
- Last update posted
- Jul 2, 2026
2024 – 2028
United States locations
- U.S. sites
- 47
- U.S. states
- 20
- U.S. cities
- 43
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Beverly Hills | California | 90211 | — |
| Research Site | La Jolla | California | 92093 | — |
| Research Site | Los Alamitos | California | 90720 | — |
| Research Site | Los Angeles | California | 90034 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Research Site | Fort Lauderdale | Florida | 33308 | — |
| Research Site | Jupiter | Florida | 33458 | — |
| Research Site | Ocala | Florida | 34474 | — |
| Research Site | Orlando | Florida | 32804 | — |
| Research Site | St. Petersburg | Florida | 33705 | — |
| Research Site | Atlanta | Georgia | 30318 | — |
| Research Site | Atlanta | Georgia | 30322 | — |
| Research Site | Honolulu | Hawaii | 96813 | — |
| Research Site | Carterville | Illinois | 62918 | — |
| Research Site | Urbana | Illinois | 61801 | — |
| Research Site | Bethesda | Maryland | 20817 | — |
| Research Site | Jamaica Plain | Massachusetts | 02130 | — |
| Research Site | Saint Paul | Minnesota | 55101 | — |
| Research Site | Kansas City | Missouri | 64132 | — |
| Research Site | St Louis | Missouri | 63128 | — |
| Research Site | Billings | Montana | 59102 | — |
| Research Site | Grand Island | Nebraska | 68803 | — |
| Research Site | Lincoln | Nebraska | 68506 | — |
| Research Site | Albany | New York | 12206 | — |
| Research Site | East Syracuse | New York | 13057 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | Shirley | New York | 11967 | — |
| Research Site | Stony Brook | New York | 11790 | — |
| Research Site | Syracuse | New York | 13210 | — |
| Research Site | The Bronx | New York | 10461 | — |
| Research Site | Cleveland | Ohio | 44111 | — |
| Research Site | Cleveland | Ohio | 44124 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Dayton | Ohio | 45459 | — |
| Research Site | Norman | Oklahoma | 73072 | — |
| Research Site | Pittsburgh | Pennsylvania | 15212 | — |
| Research Site | Sioux Falls | South Dakota | 57105 | — |
| Research Site | Memphis | Tennessee | 38120 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | Denton | Texas | 76210 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Houston | Texas | 77090 | — |
| Research Site | Kingwood | Texas | 77339 | — |
| Research Site | Fairfax | Virginia | 22031 | — |
| Research Site | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06008093, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 2, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06008093 live on ClinicalTrials.gov.